ANVS
Annovis Bio, Inc.
Set alert
1.13 USD +0.11 +10.78%
1.01 Day range 1.17
0.96 52-week range 5.10
- YTD
- -67.34%
- 1 year
- -45.67%
- Open
- 1.02
- Prev close
- 1.02
- Mkt cap
- 48.23M
- Vol
- 1.50M
- Avg vol
- 885.04K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.01
- High
- 1.17
- Forward P/E
- -2.77
- Beta
- 0.00
- Short ratio
- 6.21
- Inst. own
- 8.83%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 7.29
- 200-d avg
- 8.47
- 1y target
- 34.80
Key statistics
- Market cap
- 69.12M
- Enterprise value
- 47.66M
- Trailing P/E
- 0.00
- Forward P/E
- -2.77
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 9.42
- EPS (TTM)
- -4.22
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -11.57M
- Total cash
- 12.64M
- Total debt
- 0
- Return on equity
- -596.70%
- Shares outstanding
- 13.80M
- Short % of float
- 11.95%
- 50-day average
- 7.29
- 200-day average
- 8.47
Analyst view
Consensus: buy
Buy
Price target (mean) 34.80 +2979.6% upside
Now 1.13
- Target (low)
- 21.00
- Target (mean)
- 34.80
- Target (high)
- 72.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.20.
Financials — quick view
ANVS Revenue — quarterly 0
ANVS Net income — quarterly -14.82M
ANVS EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.64 | -0.97 | -0.33 | -51.56% |
| Aug 14, 2024 | Jun 1, 2024 | -0.70 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.70 | -0.44 | +0.26 | +37.14% |
| May 13, 2024 | Mar 1, 2024 | -0.87 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.87 | -0.72 | +0.15 | +17.24% |
| Mar 29, 2024 | Dec 1, 2023 | -1.35 | -1.09 | +0.26 | +19.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 25, 2024 | Maxim Group | up | Hold | Buy |
| Aug 15, 2024 | EF Hutton | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | EF Hutton | init | — | Buy |
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- annovisbio.com
News
- Annovis Bio Obtains Noncompliance Notice From NYSE
- Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
- Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
- Annovis to Attend the CTAD 2026 with Three Presentations
- Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease
- Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA
- Roth Capital Maintains Buy on Annovis Bio, Lowers Price Target to $7
- Annovis to Host Corporate Update Webinar on September 2, 2026
- Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Your note
Sign in to keep a note on ANVS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUCK CLAUDINE | Director | Stock Award(Grant) | Nov 19, 2023 | 7,567 |
| HAGOPIAN HENRY III | Chief Financial Officer | Stock Award(Grant) | Nov 19, 2023 | 1,824 |
| HOFFMAN MICHAEL B | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 19, 2023 | 0 |
| MACCECCHINI MARIA-LUISA | Chief Executive Officer | Stock Gift | Mar 27, 2024 | 1,068,460 |
| MCCARTHY REID S. | Director | Stock Award(Grant) | Nov 19, 2023 | 8,129 |
| WHITE MARK K. | Director | Stock Award(Grant) | Nov 19, 2023 | 61,177 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.76% | 380,255 | 1.91M | Sep 29, 2024 |
| Blackrock Inc. | 0.74% | 101,495 | 508.49K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.74% | 102,692 | 514.49K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.72% | 99,114 | 496.56K | Sep 29, 2024 |
| Group One Trading, L.P. | 0.38% | 52,767 | 264.36K | Sep 29, 2024 |
| Quest Partners LLC | 0.33% | 46,002 | 230.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.91% | 263,507 | 1.32M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 110,600 | 554.11K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 55,356 | 277.33K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.15% | 21,000 | 105.21K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.14% | 18,945 | 94.91K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 17,944 | 89.90K | Oct 30, 2024 |